Abstract
With the advent of rapid international travel, disease can now spread between nations faster than ever. As such, when outbreaks occur in foreign states, pressure mounts to reduce the risk of importing cases to the home nation. In a previous paper, we developed a model to investigate the potential effectiveness of deploying screening at airports during outbreaks of influenza, SARS, and Ebola. We also applied the model to the current COVID-19 outbreak. This model simulated the testing of travellers (assumed not to be displaying symptoms prior to boarding their flight) as they arrived at their destination. The model showed that the reduction in risk of case importation that screening alone could deliver was minimal across most scenarios considered, with outputs indicating that screening alone could detect at most 46.4%, 12.9%, and 4.0% of travellers infected with influenza, SARS and Ebola respectively, while the model also reported a detection rate of 12.0% for COVID-19. In this paper, we present a brief modification to this model allowing us to assess the added impact that quarantining incoming travelers for various periods may have on reducing the risk of case importation. Primary results show that requiring all travellers to undergo 5 days of self-isolation on arrival, after which they are tested again, has the potential to increase rates of detection to 100%, 87.6%, 81.7% and 41.3% for travellers infected with influenza, SARS, COVID-19 and Ebola respectively. Extending the period of self-isolation to 14 days increases these potential detection rates to 100%, 100%, 99.5% and 91.8% respectively.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding to declare
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Supplementary material is included at the end of the paper
